Candidiasis Therapeutics
1. Brexafemme patent expiration
Treatment: Treatment of adult and post-menarchal pediatric females with vulvovaginal candidiasis (vvc); Reduction in the incidence of recurrent vulvova...
BREXAFEMME's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8188085 | GLAXOSMITHKLINE | Antifungal agents |
Aug, 2030
(4 years from now) | |
| US10927142 | GLAXOSMITHKLINE | Salts and polymorphs of SCY-078 |
Jan, 2035
(9 years from now) | |
| US10174074 | GLAXOSMITHKLINE | Salts and polymorphs of SCY-078 |
Jan, 2035
(9 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10370406 | GLAXOSMITHKLINE | Salts and polymorphs of SCY-078 |
Jan, 2035
(9 years from now) | |
| US11534433 | GLAXOSMITHKLINE | Antifungal agents with enhanced activity in acidic pH |
Jun, 2039
(13 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Indication(I-903) | Nov 30, 2025 |
| New Chemical Entity Exclusivity(NCE) | Jun 01, 2026 |
| Generating Antibiotic Incentives Now(GAIN) | Jun 01, 2031 |
Drugs and Companies using IBREXAFUNGERP CITRATE ingredient
NCE-1 date: 01 June, 2030
Market Authorisation Date: 01 June, 2021
Dosage: TABLET
More Information on Dosage
BREXAFEMME family patents
2. Cancidas patent expiration
Treatment: Cancidas is indicated for empirical therapy for presumed fungal infections in febrile, neutropenic patients.
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5514650 | MERCK | Aza cyclohexapeptide compounds |
Jan, 2015
(10 years ago) | |
| US5792746 | MERCK | Aza cyclohexapeptide compounds |
Mar, 2013
(12 years ago) | |
| US6136783 | MERCK | Antifungal compositions |
Mar, 2017
(8 years ago) | |
|
US5792746 (Pediatric) | MERCK | Aza cyclohexapeptide compounds |
Sep, 2013
(12 years ago) | |
|
US5378804 (Pediatric) | MERCK | Aza cyclohexapeptide compounds |
Sep, 2013
(12 years ago) | |
| US5378804 | MERCK | Aza cyclohexapeptide compounds |
Mar, 2013
(12 years ago) | |
| US5952300 | MERCK | Antifungal compositions |
Mar, 2017
(8 years ago) | |
|
US5514650 (Pediatric) | MERCK | Aza cyclohexapeptide compounds |
Jul, 2015
(10 years ago) | |
|
US5952300 (Pediatric) | MERCK | Antifungal compositions |
Sep, 2017
(8 years ago) | |
|
US6136783 (Pediatric) | MERCK | Antifungal compositions |
Sep, 2017
(8 years ago) | |
Drugs and Companies using CASPOFUNGIN ACETATE ingredient
Market Authorisation Date: 26 January, 2001
Dosage: POWDER
How can I launch a generic of CANCIDAS before it's drug patent expiration?
More Information on Dosage
CANCIDAS family patents
3. Eraxis patent
expiration
Treatment: Treatment of fungal infections
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5965525 | VICURON HOLDINGS | Cyclic peptide antifungal agents |
Feb, 2020
(5 years ago) | |
| US7709444 | VICURON HOLDINGS | Echinocandin pharmaceutical formulations containing micelle-forming surfactants |
Apr, 2021
(4 years ago) | |
| US6960564 | VICURON HOLDINGS | Echinocandin pharmaceutical formulations containing micelle-forming surfactants |
Apr, 2021
(4 years ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Patient Population(NPP) | Sep 22, 2023 |
Drugs and Companies using ANIDULAFUNGIN ingredient
Market Authorisation Date: 17 February, 2006
Dosage: POWDER
More Information on Dosage
ERAXIS family patents
4. Mycamine patent expiration
Treatment: Treatment of esophageal candidiasis and prophylaxis of candida infections in hsct patients; Treatment of patients with candidemia, acute dis...
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6265536 | ASTELLAS | Cyclic hexapeptides having antibiotic activity |
Sep, 2015
(10 years ago) | |
| US6107458 | ASTELLAS | Cyclic hexapeptides having antibiotic activity |
Mar, 2019
(6 years ago) | |
|
US6774104 (Pediatric) | ASTELLAS | Stabilized pharmaceutical composition in lyophilized form |
Jul, 2021
(4 years ago) | |
| US6774104 | ASTELLAS | Stabilized pharmaceutical composition in lyophilized form |
Jan, 2021
(5 years ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Indication(I-821) | Dec 20, 2022 |
| Pediatric Exclusivity(PED) | Jun 20, 2023 |
Drugs and Companies using MICAFUNGIN SODIUM ingredient
Market Authorisation Date: 16 March, 2005
Dosage: INJECTABLE
How can I launch a generic of MYCAMINE before it's drug patent expiration?
More Information on Dosage
MYCAMINE family patents
5. Noxafil patent expiration
Treatment: Prophylaxis of invasive aspergillus and candida infections and treatment of oropharyngeal candidiasis
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5661151 | SCHERING | Tetrahydrofuran antifungals |
Jul, 2019
(6 years ago) | |
| US8263600 | SCHERING | Antifungal composition with enhanced bioavailability |
Apr, 2022
(3 years ago) | |
| US5703079 | SCHERING | Tetrahydrofuran antifungals |
Aug, 2014
(11 years ago) | |
| US6958337 | SCHERING | Crystalline antifungal polymorph |
Oct, 2018
(7 years ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Sep 15, 2011 |
| New Patient Population(NPP) | May 31, 2024 |
| New Indication(I-881) | Jun 17, 2024 |
| Orphan Drug Exclusivity(ODE-355) | Jun 17, 2028 |
Drugs and Companies using POSACONAZOLE ingredient
NCE-1 date: 15 September, 2010
Market Authorisation Date: 15 September, 2006
Dosage: SUSPENSION
How can I launch a generic of NOXAFIL before it's drug patent expiration?
More Information on Dosage
NOXAFIL family patents
6. Noxafil patent expiration
Treatment: Prophylaxis of invasive aspergillus and candida infections in adults and pediatric patients 2 years of age and older who are severely immunocompromised; Prophylaxis of invasive aspergillus and candida...
NOXAFIL's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US5661151 | MERCK SHARP DOHME | Tetrahydrofuran antifungals |
Jul, 2019
(6 years ago) | |
| US5703079 | MERCK SHARP DOHME | Tetrahydrofuran antifungals |
Aug, 2014
(11 years ago) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9358297 | MERCK SHARP DOHME | Posaconazole intravenous solution formulations stabilized by substituted β-cyclodextrin |
Jun, 2031
(5 years from now) | |
| US9023790 | MERCK SHARP DOHME | Posaconazole intravenous solution formulations stabilized by substituted β-cyclodextrin |
Jul, 2031
(5 years from now) | |
| US9750822 | MERCK SHARP DOHME | Sulfoalkyl ether cyclodextrin compositions |
Mar, 2029
(3 years from now) | |
| US9493582 | MERCK SHARP DOHME | Alkylated cyclodextrin compositions and processes for preparing and using the same |
Feb, 2033
(7 years from now) | |
| US10117951 | MERCK SHARP DOHME | Sulfoalkyl ether cyclodextrin compositions |
Mar, 2029
(3 years from now) | |
| US8410077 | MERCK SHARP DOHME | Sulfoalkyl ether cyclodextrin compositions |
Mar, 2029
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Sep 15, 2011 |
| New Patient Population(NPP) | May 31, 2024 |
| New Indication(I-881) | Jun 17, 2024 |
| Orphan Drug Exclusivity(ODE-355) | Jun 17, 2028 |
Drugs and Companies using POSACONAZOLE ingredient
Market Authorisation Date: 13 March, 2014
Dosage: SOLUTION; TABLET, DELAYED RELEASE
How can I launch a generic of NOXAFIL before it's drug patent expiration?
More Information on Dosage
NOXAFIL family patents
7. Rezzayo patent expiration
Treatment: Treatment of candidemia and invasive candidiasis with rezafungin by intravenous administration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US10702573 | MUNDIPHARMA | Dosing regimens for echinocandin class compounds |
Mar, 2033
(7 years from now) | |
| US9526835 | MUNDIPHARMA | Dosing regimens for echinocandin class compounds |
Mar, 2033
(7 years from now) | |
| US8722619 | MUNDIPHARMA | Antifungal agents and uses thereof |
Mar, 2032
(6 years from now) | |
| US11197909 | MUNDIPHARMA | Compositions and methods for the treatment of fungal infections |
Jul, 2038
(12 years from now) | |
| US11654196 | MUNDIPHARMA | Dosing regimens for echinocandin class compounds |
Mar, 2032
(6 years from now) | |
| US11819533 | MUNDIPHARMA | Compositions and methods for the treatment of fungal infections |
Jul, 2038
(12 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11712459 | MUNDIPHARMA | Dosing regimens for treatment of fungal infections |
Mar, 2037
(11 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Mar 22, 2028 |
| Orphan Drug Exclusivity(ODE-426) | Mar 22, 2030 |
| Generating Antibiotic Incentives Now(GAIN) | Mar 22, 2033 |
Drugs and Companies using REZAFUNGIN ACETATE ingredient
NCE-1 date: 22 March, 2032
Market Authorisation Date: 22 March, 2023
Dosage: POWDER
More Information on Dosage
REZZAYO family patents
8. Vivjoa patent expiration
Treatment: Vivjoa is indicated to reduce the incidence of recurrent vulvovaginal candidiasis (rvvc) in females with a history of rvvc who are not of re...
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8236962 | MYCOVIA PHARMS | Metalloenzyme inhibitor compounds |
Apr, 2031
(5 years from now) | |
| US9840492 | MYCOVIA PHARMS | Antifungal compounds and processes for making |
Mar, 2036
(10 years from now) | |
| US10414751 | MYCOVIA PHARMS | Antifungal compounds and processes for making |
Mar, 2036
(10 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11247981 | MYCOVIA PHARMS | Metalloenzyme inhibitor compounds |
May, 2033
(7 years from now) | |
| US8754227 | MYCOVIA PHARMS | Metalloenzyme inhibitor compounds |
Apr, 2031
(5 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Apr 26, 2027 |
| Generating Antibiotic Incentives Now(GAIN) | Apr 26, 2032 |
Drugs and Companies using OTESECONAZOLE ingredient
NCE-1 date: 27 April, 2031
Market Authorisation Date: 26 April, 2022
Dosage: CAPSULE
More Information on Dosage
VIVJOA family patents